By THE ASSOCIATED PRESSJAN. 4, 2016
Approvals for first-of-a-kind drugs climbed last year, pushing the annual tally of new United States drugs to its highest level in 19 years. The rising figures reflect an industrywide focus on drugs for rare and hard-to-treat diseases, which often come with streamlined regulatory reviews, extra patent protections and higher price tags. The Food and Drug Administration approved 45 drugs with never-before-sold ingredients in 2015, edging past the previous year’s tally of 41 and the highest number since 1996. Analysts say drug makers are getting better at picking the most promising drugs in their research and development pipelines. Between 2007 and 2011, only one in 19 drugs entering early-stage testing actually reached the market, according to industry data analyzed by Tim Anderson of Sanford C. Bernstein & Company. Today, one in 13 early-stage drugs makes it to market. “These improvements hopefully reflect the pay-off from the industry’s conscious decade-long efforts to ‘turn around’ R&D,” Mr. Anderson told investors in a research note last year.A version of this brief appears in print on January 5, 2016, on Page B2 of the New York edition with the headline: F.D.A. Drug Approvals Climb to Highest Level Since 1996.  Order Reprints| Today's Paper|Subscribe

We’re interested in your feedback on this page. Tell us what you think.